Source: PR NEWSWIRE

Press Release: Lpath : Lpath to Present Nexus Phase 2 Study Data in Wet Age-Related Macular Degeneration at the 2015 American Academy of Ophthalmology Annual Meeting Retinal Subspecialty Day

SAN DIEGO, Nov. 5, 2015 /PRNewswire/ -- Lpath, Inc. (NASDAQ: LPTN), the industry leader in bioactive lipid-targeted therapeutics, announced that data from the Nexus Phase 2 study of iSONEP will be presented at the upcoming American Academy of Ophthalmology (AAO) Annual Meeting...

Read full article »
Est. Annual Revenue
$25-100M
Est. Employees
100-250
CEO Avatar

CEO

Gary J. G. Atkinson

CEO Approval Rating

69/100

Read more